Taurine, a sulfur amino acid, is present in abundant amounts in ells throughout the body. The kidney regulates taurine balance by modulating proximal tubule reabsorption in response to fluctuations in dietary intake of this nutrient. There is no information about the localization of taurine within the kidney in normal and diseased renal parenchyma. Therefore, using an antibody to a taurine-glutaraldehyde-BSA conjugate, we examined the distribution of taurine in renal tissue. Normal rats, those with streptozocin diabetes, puromycin aminonudeoside nephropathy, bilateral ureteral ligation, and 516 nephrectomy were studied. In normal animals, taurine was found primarily in medullary tubules, with minimal staining of proximal tubules and glomeruli. There was increased taurine staining of all structures, especially medullary tubules, in rats with streptozocin diabetes 1H3)
Introduction
Taurine (2-aminoethane sulfonic acid) is a ubiquitous molecule in the body and is the most abundant free amino acid in the cytosol of many organs (1, 2) . Taurine is available from dietary sources and can also be synthesized from cysteine via cysteinesulfinic acid decarboxylase (3). The kidney regulates total body taurine balance by modulating proximal tubule reabsorption in response to fluctuations in nutritional intake (4-6). However, no studies have examined the localization of taurine in renal tissue.
Taurine has many biological functions, including bile acid conjugation and retinal photoreceptor cell stabilization (2). It contributes to cerebral cell volume regulation during osmolal stress by acting as a compatible, non-perturbing organic osmolyte (7,8). Taurine possesses membrane-stabilizing and antioxidant properties and protects cells from oxygen free radical-induced injury (9,lO and puromycin aminonudeoside nephropathy. These changes were more pronounced in diabetic rats and were unrelated to renal medullary osmolality. The distribution of taurine within the kidney was unchanged in the models of acute and chronic renal failure. Alterations in the immunohistochemical localization of taurine correlated with the beneficial effect of this amino acid to preserve renal function in the rats with chronic diabetes and puromycin aminonudeoside nephropathy. These results suggest that taurine is preferentially localized in the medullary regions of the kidney, where it exerts a protective effect against renal injury in select disease states. ( J Histochem Cytochem 41:1209-1216, attenuates the progressive decline in renal function and structural damage. These beneficial effects of taurine supplementation have been related to its capacity to act as an anti-oxidant (11) . To elucidate the mechanism of taurine's protective action in models of renal disease, we conducted immunohistochemical studies to localize taurine within normal and diseased renal parenchyma.
Materials and Methods
Animals. Male Sprague-Dawley rats, weighing 150-250 g at the start of each protocol, were used in these experiments. They were housed in a facility that was maintained at 25°C with a 12-hr light-dark cycle. They were given water to drink ad libitum and were fed rodent laboratory chow no. 5001, containing 22% protein (Purina Mills; St Louis, MO). Although the manufacturer does not routinely measure the taurine content of the pelleted food, we have determined that most batches contain 3-4 pmol taurinelg chow. Disease Models. Diabetes was induced by a single intravenous injection of streptozocin, 60 mglkg body weight (12). Rats were given 10% glucose to drink for the initial 48 hr to prevent hypoglycemia. Two rats were housed per cage to prevent dehydration. Diabetic animals were followed for 40 weeks without receiving any insulin treatment.
Chronic puromycin aminonudeoside (PAMN) nephropathy was induced over 12 weeks by sc injections of the toxin, 2 mgllOO g body weightldose.
TRACHTMAN, LU, STURMAN on days 1, 8, 15, 29,43,47, 71 (13). This protocol results in severe proteinuria and histopathological evidence of focal segmental glomerulosclerosis. Acute renal failure (ARF) was produced by bilateral ureteral ligation. Animals were maintained for 48 hr before sacrifice (14). Sham-operated animals were included for comparison purposes.
Chronic renal failure (CRF) was induced in a one-step procedure by unilateral right nephrectomy and surgical removal of 50-60% of the contralateral renal tissue (15). Rats were maintained for 3 months before sacrifice. Sham-operated animals were included for comparison purposes.
Normal rats that were free of renal disease were studied at comparable ages to the animals in the various experimental groups.
The disease-free rats and those with diabetes and chronic PAMN nephropathy were randomly assigned to a control group given tapwater and an experimental group given 1% taurine-supplemented drinking water. The animals with ARF, CRF, and sham-operated rats received only untreated tapwater.
All experimental protocols were approved by the Long Island Jewish Medical Center Internal Animal Care and Use Committee.
Immunohistochemical Technique. Three rats from each group were sacrificed without any prior interval of food or water deprivation and the kidneys were rapidly removed. The tissue was sectioned into approximately 2-mm slices and immersed in cold fixative solution containing 1% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M PBS, pH 7.4, for 24 hr. Followup studies were done to confirm the efficacy of immersion vs perfusionfixation as a means of demonstrating the immunohistochemical localization of taurine within renal tissue. In two rats from each group the kidneys were perfused with cold fixative solution at systemic blood pressure levels via a catheter that was inserted into the right external jugular vein and advanced into the right atrium.
Immunogens were synthesized by the method of Campistron et a1 (16), starting with 100 mg of taurine, GABA, palanine, or glycine, and coupling with glutaraldehyde to bovine serum albumin (BSA) or poly-L-lysine (PL), MW 30,000-70.000 (Sigma; St Louis, MO).
Rabbits were immunized by first injecting 500 pg of immunogen emulsified in Freund's complete adjuvant, followed every 4 weeks by injection of 500 pg immunogen in Freund's incomplete adjuvant. Injection alternated glutaraldehyde-BSA and glutaraldehyde-PL conjugates of taurine or GABA. Two rabbits were injected subcutaneously and two intramuscularly. Blood was collected 7 and 21 days after injection and serum frozen in 1-ml batches.
Table 1. Renal function in rats with experimental Ridney &seas@
The serum was characterized for titer and crossreactivity by the ELISA method (17). High, stable titers of reactivity against taurine-glutaraldehyde-BSA were reached after three injections (>1:664,000 dilution). This serum had a small reactivity to GABA-glutaraldehyde-BSA and to !3-alanineglutaraldehyde-BSA that was removed by pre-absorption with both conjugates, resulting in little loss of specific taurine-glutaraldehyde-BSA immunostaining. Further purification of the antiserum was accomplished with a Protein G Sepharose column (MAbTrap G Pharmacia, Piscataway, NJ). Similar steps were utilized for purification of the anti-GABA antibody. Additional proof that the GABA antibody did not react with other tissue constituents was the absence of binding to muscle tissue that normally does not contain GABA (18).
Tissue was embedded in parafilm and 6-pm sagittal sections were cut and mounted on glass slides. Sections were deparaffinized and dehydrated by warming at 60°C for 1 hr and 5 min in a histoclear bath, followed by graded ethanol washes. Staining with taurine or GABA antiserum (1:lOOO dilution, or 1:lOO when the purified antiserum was used) was carried out overnight at 4% and was visualized by the biotin-avidin-peroxidase4aminobenzidine method (Dako; Carpinteria, CA) (19). The results were similar when the two antisera were used with different dilutions. Control sections were included in every batch, those in which the antiserum was pre-absorbed with the immunogen before processing, and others replacing the primary antiserum with pre-immune serum at similar dilutions. Control slides showed no visible staining, whereas slides prepared with the taurine or GABA antisera showed brown reaction products. Photomicrographs were taken on a Zeiss 111 photomicrograph using Kodak 25 color reversal film (20).
Renal Pathology Assessment. Segmental glomerulosclerosis was defined as localized collapse of capillary lumina and replacement with eosinophilic hyalinized material, occasionally accompanied by adhesions to Bowman's capsule. The number of segmentally sclerosed glomeruli was expressed as a percentage of the total number of glomeruli examined. This exceeded 200 in all animals. The tubulointerstitial injury was graded on a scale of 0-4+ depending on whether 0, <lo%, 10-25%, 25-50%, or >50% of the renal parenchymal displayed tubule dilatation and atrophy and interstitial fibrosis.
Analytical Techniques. Serum and urine creatinine concentrations were measured with an automated analyzer (Beckman; Fullerton, CA). Urinary protein and albumin concentrations were determined with the Coomassie blue binding (Bio-Rad; Richmond, CA) and bromcresol green (Sigma) re- agents, respectively. Plasma and renal tissue taurine and GABA levels were assayed by reverse-phase HPLC and pre-column derivatization with phenylisothiocyanate and were quantified using Nelson Analytical 2600 chromatography software with a desktop computer (21). Renal medullary tissue osmolality was determined by removing the cortical tissue and placing portions of kidney parenchyma (160-340 mg) in 1 ml of boiling water for 60 min and measuring the osmolality with a vapor pressure osmometer (Wescor; Logan, UT).
Statistical Analysis. The differences in the mean values between groups were compared using Student's t-test or an analysis of variance. The results were considered statistically significant if the p value was less than 0.05.
Results
After administration of STZ, there was chronic hyperglycemia, the serum glucose concentrations at 40 weeks were 31.7 * 0.9 and 31.5 * 1.2 mM in the untreated and the taurine-supplemented rats, respectively. The animals with chronic PAMN nephropathy had an increase in urinary protein excretion withm 2 weeks. Rats with ARF or CRF had the expected impairment of kidney function.
Normal rats displayed no segmental glomerulosclerosis and were free of any tubulointerstitial changes; administration of taurine did not alter renal structure. In animals with diabetic nephropathy, taurine treatment resulted in less glomerulosclerosis (4.0 * 1.8 vs 0.78 -c 0.33,p<0.025) and tubulointerstitial damage (0.8 * 0.2 vs 0.2 2 o.l,p<o.o4). Dietary taurine supplementation reduced the number of segmentally sclerosed glomeruli and decreased the severity of tubulointerstitial injury in rats with chronic PAMN nephropathy, as previously reported (11) .
The assessment of kidney function in the experimental groups, including serum creatinine concentration, creatinine clearance, and urinary albumin excretion [albumin (mg/dl), creatinine (mg/dl)] is summarized in Table 1 . Taurine administration had no demonstrable effect in normal rats. Dietary taurine supplementation reduced albuminuria in the STZ diabetic rats, 13.6 f 2.7 vs 20.9 * 2.6,p=0.07. The glomerular filtration rate (GFR), using creatinine clearance as an index of renal function, was higher in taurinetreated diabetic rats compared with untreated animals, 0.70 * 0.06 vs 0.48 0.04 mllminllOO g body weight, p<O.Ol. In rats with chronic PAMN nephropathy, taurine treatment also resulted in decreased albuminuria and stabilization of GFR (11). We have previously demonstrated that administration of taurine does not improve renal function in rats with ARF or CRF (22).
The renal parenchymal taurine content in the experimental groups is shown in Table 2. The kidney taurine level was significantly higher in diabetic compared with normal rats. Dietary taurine supplementation increased the level of this amino acid in kid- 18.5 f 1.1 (6)6 Diabetes 6.8 f 1.0 (8)6 13.6 f 0.9 ( phology of positively stained tubules suggested that the bulk of the taurine was present in the thick ascending limb of Henle and the collecting ducts. Taurine administration resulted in a mild increase in the intensity of staining but did not affect the distribution of the amino acid within the kidney (Figures 2a-2c) . Chronic diabetes and PAMN nephropathy were associated with enhanced staining for taurine in renal tissue ( Figures Id-f and li) . The most profound changes were observed in medullary tubules, in which an intense taurine-positive cap was present along the apical membrane. In addition, taurine staining was evident in other nephron segments that did not normally contain taurine, such as the proximal tubule, in both disease states. The intensity of glomerular staining for taurine was mildly increased in rats with chronic diabetes and PAMN nephropathy. The magnitude of these changes was more pronounced in the diabetic rats compared with those with PAMN nephropathy. Oral supplementation of taurine exaggerated the changes in taurine staining in the collecting ducts, proximal tubules and glomeruli in these two conditions (Figures 2d-2 ). The differences in the renal immunohistochemical staining for taurine in control, diabetic, and PAMN nephropathy rats were unrelated to the medullary tissue osmolality.
There was no alteration in the tissue staining or distribution of taurine in animals with CRF compared with sham-operated rats ( Figure Ih) . In rats with ARF after bilateral ureteral ligation, there was a modest increase in the amount of taurine visualized within the lumens of medullary tubules ( Figure Ig) .
Further experiments were performed in which kidneys were immersion-fixed as described above and others were perfusion-fixed. Two rats from each experimental group were subjected to the different tissue preparation techniques. Sections of each kidney speciney tissue of normal, diabetic, and PAMN nephropathy rats. The osmolality of the renal medullary tissue in normal, STZ diabetic and PAMN nephropathy rats was comparable and was not affected by the administration of taurine (Table 3) .
Three animals in each category were included in the immunohistochemical studies. In normal rats, staining for taurine was ob- served in the medullary regions of the kidney and to a lesser degree in glomeruli (Figures la-lc) . Taurine was not present in the men were processed on the same slide for immunohistochemical localization of taurine. There was no discernible difference between any of the pairs in staining intensity or localization of taurine in any of the disease states examined (data not shown).
A recent report has demonstrated GABA immunoreactivity in the kidney (23). Therefore, we measured renal GABA content (n = 4) and GABA distribution (n = 3) by immunohistochemistry to determine whether STZ diabetes and PAMN nephropathy have a similar effect on the localization of taurine and GABA in renal tissue. In contrast to the increased renal taurine content in STZ diabetic and PAMN nephropathy rats, the amount of GABA in the kidney was reduced in these two disease states ( Table 4 ). In normal kidneys, the intrarenal distribution of GABA was similar to that of taurine, except for a slightly accentuated pattern of staining in the cortical regions and the proximal tubules. However, in contrast to taurine, the immunohistochemical detection of GABA was diminished in rats with STZ diabetes and PAMN nephropathy.
Discussion
During the past decade there has been intense interest in the biological functions of taurine. Despite recognition of the pivotal role of the kidney in the regulation of taurine balance, our study is the first to examine the localization of this amino acid in the renal parenchyma in normal and disease states.
The source of taurine is dietary intake and biosynthesis (3). Taurine is reabsorbed by the kidney; the avidity of renal reclamation of taurine is inversely related to its nutritional availability (4,6,24) . The Na+ and Cl--dependent p-amino acid transporter responsible for taurine reabsorption is located in the proximal tubule brush border membrane (5,24). Thus, the altered renal content and distribution of taurine in rats with chronic diabetes and PAMN nephropathy is not a consequence of enhanced uptake in the proximal tubule. The predominant immunohistochemical localization of taurine in medullary tubules is consistent with the divergent pattern of apical and basolateral membrane uptake of taurine in vitro in LLC-PK1 and MDCK cells (25). Differences in taurine localization among the experimental models of renal injury, i.e., STZ diabetes and PAMN nephropathy vs ARF and CRF, indicate that our findings are not a nonspecific artifact of acute or chronic kidney disease. The more impressive changes observed in STZ diabetes compared with PAMN nephropathy reflect less advanced renal parenchymal destruction seen in the former disorder.
Conclusions about the intrarenal distribution of taurine using immunohistochemical techniques rely on the assumption that no 0.05 (4) redistribution occurs during fixation. That this assumption is correct is supported by our fiidings of identical results with immersionand perfusion-fixed kidneys and by several studies. In one, [3%]taurine was injected IP into rats that were killed 24 hr later under pentobarbital anesthesia by one of the following methods: (a) intracardiac perfusion with paraformaldehyde and glutaraldehyde for 15 min and olfactory bulbs removed; (b) decapitation and olfactory bulbs removed and immersed in the same fixative; and (c) decapitation and olfactory bulbs removed and immediately frozen in liquid dichlorofluoromethane (26). Tissues processed in the three different ways contained similar amounts of radioactivity and showed similar distributions of radioactivity after sectioning and autoradiography. The only difference was that all radioactivity in the frozen tissue was water soluble and was present as [3%]-taurine, whereas no radioactivity in the two fixed samples was water soluble. A more recent study examined the distribution of taurine in muscle tissue utilizing the same immunohistochemical methods described in this report (18) . A comparison was made between immersion-and perfusion-fixed tissue samples from the same animal by clamping a leg under deep anesthesia and removing it for immersion-fixation before intracardiac perfusion. An identical distribution of taurine and glutamate was observed in all tissue samples examined. Finally, the group of investigators who pioneered the production and use of conjugated amino acid antibodies has studied this issue intensively and has found no evidence of redistribution of amino acids during fixation (27).
The studies of GABA content and distribution in the kidney support our contention that inuarenal localization of taurine is specifically altered in select disease states. Parduct et al. (23) have demonstrated that there are GABA-immunoreactive structures in the rat kidney. We confirmed that there was a measurable amount of GABA within the rat kidney; however, renal GABA content was diminished in the disease states, especially in the STZ diabetic rats. In addition, the immunohistochemical localization of GABA in the kidney was slightly different from that of taurine, with more prominent staining in the cortical vs medullary zones. Furthermore, the intensity of GABA staining was reduced in rats with STZ diabetes and PAMN nephropathy. The disparate effects of these two experimental diseases on the renal content and the distribution of taurine and GABA indicate that the changes observed for taurine are relevant to their undeilying pathophysiology.
Taurine is acerebral organic osmolyte. Nakanishi et al. (28) have demonstrated in rats that the renal tissue level of taurine in the inner medulla rises and falls during antidiuretic and diuretic states, respectively. They concluded that this amino acid also functions as an osmolyte in the kidney. In our studies there was no correlation between the renal tissue osmolality and the immunohistochemical distribution of taurine in the various disease states. Therefore, our findings cannot be ascribed to taurine's role in renal cell volume regulation.
Lipid peroxidation of cell membranes has been implicated in organ damage in diabetes and PAMN nephropathy. Hyperglycemia directly causes injury to erythrocyte membranes in association with excessive production of oxygen free radicals, reduced vitamin E levels, and increased lipofuscin products (29,30). Retinal, neu-=Mean ? SEM. STZ diabetes and PAMN nephropathy. ronal, and muscle damage in experimental diabetes has been attributed to reactive oxygen molecules (31.32). In acute PAMN nephropathy, treatment with inactivators or scavengers of oxygen free b Numbers in patentheses indicate how many animals were included in each experimental group. radicals attenuates proteinuria and diminishes glomerulosclerosis and tubulointerstitial scarring (33,34). Increased production of oxygen free radicals in chronic renal disease could occur by two mechanisms. A decrease in kidney mass results in an adaptive increase in the reabsorption of Na+ and other solutes by surviving nephrons, which necessitates enhanced metabolic activity by the tubules (35,36) . This hypermetabolic state leads to increased generation of toxic free radical species in the renal tubulointerstitium (37). Alternatively, CRF with sustained proteinuria may stimulate macrophages and monocytes to infiltrate the medullary portions of the kidney parenchyma (38,39) . These activated, immunocompetent cells may produce excessive quantities of oxygen free radicals that overwhelm local enzymatic detoxification mechanisms (40). In both scenarios, the principal site of abnormal oxygen free radical production is the tubulointerstitial region.
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Eurine is an antioxidant that scavenges extracellular oxidants such as hypochlorous acid (HOCI) by forming less toxic taurine chloramines (41). At physiological pH, taurine is a zwitterion that penetrates cell membranes and prevents the intracellular production of oxygen free radicals. It intekres with the action of metalloprotein complexes that are responsible for the cytosolic generation of reactive oxygen molecules (42). Eurine protects biomembranes against in vitro oxidant stress (43). It limits oxygen free radical damage to alveolar macrophages and lung tissue after exposure to ozone or bleomycin, respectively (44,45).
We have demonstrated increased intensity and more widespread taurine-specific immunostaining within the renal tubulointerstitium in rats with chronic STZ diabetes and PAMN nephropathy. This amino acid may be preferentially localized to these regions in these two disease states, an adaptation designed to limit progressive renal injury by virtue of the anti-oxidant properties of taurine.
Our data indicate that taurine is not uniformly involved in ameliorating kidney disease in experimental models. There may be differences in the role of oxygen free radicals as mediators of kidney injury. Alternatively, the ability of taurine to reduce peroxidative damage may vary depending on the intrarenal balance between oxygen free radical production and endogenous tissue defense mechanisms (46). Administration of free radical scavengers or inactivators attenuates the severity of ARF after bilateral renal artery clamping and reperfusion (47) and after exposure to nephrotoxic agents (48.49). Oxygen free radicals may not contribute to the sudden decline in GFR after bilateral ureteral ligation. The increased amounts of taurine within the lumen of medullary tubules in the rats with ARF may reflect severe renal insult, complete cessation of urine flow, and interference with normal amino acid transport processes in the loop of Henle (50). The renal production of reactive oxygen molecules is not enhanced in the remnant kidney model of CRF (51). The inability of taurine to improve renal function in the models of ARF and CRF is consistent with the failure to detect the same pattern of increased taurine staining in the tubulointerstitial regions of the kidney seen in rats with diabetes or chronic PAMN nephropathy.
In summary, we have used immunohistochemical techniques to investigate the intrarenal distribution of the amino acid taurine within the renal parenchyma. Under normal circumstances, taurine is localized primarily in tubule structures in the medulla, with faint staining present in pmimal tubules and glomeruli. Furthermore, we have demonstrated that there is a significant concordance 1215 between the effect of taurine supplementation on renal structure and function in a range of experimental kidney disease states and the pattern of localization of the amino acid within the renal parenchyma. In conditions in which taurine exerted a protective effect on kidney function (diabetic nephropathy and PAMN nephropathy), there was enhanced medullary tubule staining for the amino acid. Under circumstances in which taurine treatment did not attenuate renal failure (ARF due to bilateral ureteral ligation and CRF due to 75% reduction in kidney mass), there was no change in the pattern of renal localization of the amino acid.
